Improving Gross-to-Net Performance with Optimized Channel Data Platform

IntegriChain was approached by a top-20 pharma manufacturer has a wide range of specialty, orphan/rare, and traditional brands across more than eight therapeutic categories. As a result of their evolution into precision medicine, their channel data strategies were becoming dated and they had become frustrated with the lack of actionable data and timely insights from their current data aggregator. As a result, the customer had “blind spots” in their ability to properly manage and optimize their channel operations as well as achieve accurate gross-to-net (GTN) forecasts. Download below!